• Yuerong Gui, Qing Pang, WangShuoSGuang'an men Hospital, China Academy of Chinese Medical Sciences, China.Beijing University of Chinese Medicine, China., Jun Dong, Dandan Wang, Xiumei Ma, Xinyan Wang, Shuaihang Hu, and Wei Hou.
• Guang'an men Hospital, China Academy of Chinese Medical Sciences, China.
• Medicine (Baltimore). 2022 Feb 25; 101 (8): e28929e28929.

BackgroundRadiation pneumonitis is a common dose-limiting factor in radiotherapy for thoracic malignancies, and its treatment encounters a bottleneck. As an essential adjuvant treatment method, Chinese herbal injections (CHIs) have been used to treat radiation pneumonitis (RP), and clinical studies have appeared potentially beneficial and nontoxic. However, the efficacy and safety of CHIs for RP have not been evaluated comprehensively.MethodsThe systematic review and meta-analysis will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. The Cochrane Library, PubMed, EMBASE, SinoMed, CNKI, VIP, and Wan Fang Databases were systematically searched from inception until January 20, 2022. The selection of studies, data extraction, and assessment of the risk of bias will be performed by 2 reviewers independently. The total effective rate was used as a primary outcome measure; the secondary outcomes are quality of life, clinical symptoms and signs, inflammatory cytokines, and adverse effects. Cochrane Review Manager (RevMan5.3) software will be used for data synthesis and analysis.Results And ConclusionThis systematic review will evaluate the efficacy and safety of CHIs in treating radiation pneumonitis to provide more comprehensive evidence for the treatment of clinical RP.Inplasy Registration NumberINPLASY202210106.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…